Arcutis Biotherapeutics Soars on Zoryve Success and Bullish Analyst Ratings

TipRanksDec 18 04:53 ET

Arcutis Submits ZORYVE (Roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis

GlobeNewswireDec 16 08:00 ET

Express News | Arcutis Submits Zoryve® (Roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis

ReutersDec 16 08:00 ET

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Warby Parker (WRBY)

TipRanksDec 16 01:50 ET · Ratings

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireDec 6 16:00 ET

Express News | Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersDec 6 16:00 ET